Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial

This piece of research has lead to a practice changing update on DynaMed Plus. It concludes that the addition of trastuzumab biosimilar to taxane-based chemotherapy is associated with similar overall response and survival rates compared to addition of trastuzumab in women with HER2-positive metastatic breast cancer
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news